Acomplia and OTC orlistat for weight loss

March 2006

There's a lot of buzz about Acomplia and OTC orlistat for weight loss. Both could be approved as early as this summer.

Alli (AL-eye) will be OTC orlistat...half the strength of prescription Xenical.

GlaxoSmithKline hopes to market Alli for short-term use... 6 months or less...in people who are overweight.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

MedGuides are piling up on many pharmacy counters
Cardiology Ranexa (ranolazine) for chronic angina
Cardiology LOW-dose vitamin K supplements to stabilize the effect of warfarin in certain patients
Osteoporosis IV form of Boniva (ibandronate)
whether saw palmetto is effective for benign prostatic hyperplasia (BPH)
American Heart Association now says NOT to rely on soy protein or isoflavone supplements to prevent heart disease
Diabetes whether sulfonylureas increase mortality
Diabetes Many patients are looking forward to trying the new inhaled insulin, Exubera
Diabetes Apidra (insulin glulisine) is the newest rapid-acting insulin
Statins how to monitor for myopathy in patients taking statins
FDA will likely pull epinephrine inhalers (Primatene Mist, etc) off the market
Kidney Disease Even patients with SEVERE kidney disease seem to benefit from ACE inhibitors
Obesity & Weight Loss Acomplia and OTC orlistat for weight loss
Infectious Diseases possible liver toxicity in patients taking Ketek (telithromycin)
Infectious Diseases Tequin (gatifloxacin) is now contraindicated for diabetes patients